

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

COMPLETION OF THE H SHARE FULL CONVERSION PLAN

References are made to (i) the announcement of the Company dated 22 November 2019 in relation to participation in the H share full circulation project by the Company to convert and list the Domestic Shares held by the Participating Shareholder into H Shares; (ii) the announcement of the Company dated 3 June 2020 in relation to the Company having received an official acceptance letter in relation to the application for full circulation of H Shares by the Company from CSRC; and (iii) the announcement of the Company dated 19 August 2020 in relation to the granting of the Listing Approval by the Hong Kong Stock Exchange (collectively, the “**Announcements**”). Unless otherwise indicated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company is pleased to announce that the share certificate for the Converted H Shares has been issued to China Securities Depository and Clearing (Hong Kong) Company Limited and deposited into CCASS operated by the Hong Kong Securities Clearing Company Limited on 2 September 2020 and such Converted H Shares will be listed on the Hong Kong Stock Exchange at 9:00 a.m. on 3 September 2020 as scheduled.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
2 September 2020

As of the date of this announcement, the board of the Company consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive Directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao and Ms. XIANG Ling as independent non-executive Directors.